, is a high density lipoprotein receptor that mediates the flux of cholesterol between high density lipoprotein and cells. Recent evidence suggests that SR-BI plays a role in atherosclerosis and that inflammatory mediators downregulate SR-BI in the macrophage. The purpose of this study was to evaluate the ability of lipopolysaccharide (LPS) to down-regulate the activity of the human SR-BI promoter in the macrophage and to delineate the mechanisms involved. Experiments with cultured cells and in vivo derived macrophages showed that LPS has a powerful suppressive effect on SR-BI expression both in vitro and in vivo. Transient transfection studies demonstrated that LPS represses SR-BI promoter activity in the macrophage cell line RAW 264.7. Cotransfection with either a constitutively active p21-activated protein kinase-1 (PAK1) construct (T423E) or a kinase-deficient PAK1 construct (K299R) resulted in repression of the SR-BI promoter, similar to LPS. These results demonstrate that PAK1-mediated down-regulation of the SR-BI promoter is independent of PAK1 kinase activity and suggest that PAK1 mediates the LPS-induced decrease in promoter activity. Cotransfection with constitutively active Cdc42 or Rac expression constructs also resulted in down-regulation of the promoter; whereas the dominant-negative Cdc42 and Rac constructs elevated basal promoter activity and blunted the LPS response. Cotransfection of PAK1 constructs containing mutations in both the kinase domain and the Cdc42/Racbinding domain attenuated the PAK1-mediated downregulation of the promoter, suggesting that Rac and Cdc42 are required for PAK1-mediated decreases in SR-BI promoter activity. 5-Deletion analysis and gel shift data suggest that LPS inhibits binding of a novel transcription factor to a myeloid zing finger protein-1-like element (؊476 to ؊456) in the human SR-BI promoter. These results demonstrate that the PAK1 pathway down-regulates the SR-BI promoter and suggest that activation of this pathway may play an important role in cholesterol trafficking in the vessel wall.
Scavenger receptor class B, type I (SR-BI), 1 is a high density lipoprotein receptor that mediates both the influx (1-3) and efflux (4, 5) of cholesterol between high density lipoprotein and cells. Prominent expression of SR-BI has been observed in the liver and steroidogenic tissues (1, 2, 6, 7) and more recently in the macrophage and atherosclerotic vessel wall (2, 4, 8, 9) . Although the contribution of SR-BI in the vessel wall to atherogenesis is not known, hepatic overexpression of SR-BI reduces atherosclerosis in low density lipoprotein receptor-deficient mice fed a high fat diet. Because this effect is associated with reduced plasma high density lipoprotein, it has been suggested that SR-BI enhances hepatic uptake of high density lipoprotein cholesterol and thereby suppresses atherogenesis (10, 11) . Consistent with this, crossing of SR-BI knockout mice with apoE knockout mice accelerates the onset of atherosclerosis (12) , again suggesting an atheroprotective role for SR-BI. A variety of stimuli have been demonstrated to regulate SR-BI expression. The hormones estrogen and adrenocorticotropic hormone have been observed to alter SR-BI expression (7, (13) (14) (15) . In addition, modified low density lipoprotein has been shown to increase SR-BI in human monocyte-derived macrophages (8) , whereas high cholesterol diet lowers SR-BI expression in rat liver parenchymal cells (15) . Pro-inflammatory mediators such as lipopolysaccharide (LPS) have also been shown to down-regulate the mRNA and protein levels of SR-BI in the monocyte and macrophage (16) . Despite a number of studies demonstrating regulation of SR-BI, relatively little is known about the basic mechanisms involved. Recent promoter studies have shown that members of the Sp1 transcription factor family are essential for transcription of the rat SR-BI gene in mouse Leydig tumor cells (17) . It has also been shown that the sterol response element-binding protein activates transcription of the rat SR-BI promoter in variety of cell lines (18) and that steroidogenic factor-1 binds to and activates the human SR-BI promoter in mouse adrenocortical cells (6) . More recently, it was shown that the ligand-activated peroxisome proliferator-activated receptor increases SR-BI expression in human monocytes and macrophages (9) .
The observation that pro-inflammatory stimuli such as LPS repress SR-BI expression has led to the hypothesis that inflammatory mediators contribute to atherogenesis by compromising cholesterol efflux from vascular macrophages. LPS is known to signal through Toll-like receptor-4 (19) and to trigger the activation of nuclear factor-B (NF-B) plus several MAPKs, the ERK, p38, and JNK proteins (20 -24) . In addition, LPS has * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
been shown to activate p21-activated kinase-1 (PAK1) in the macrophage, and PAK1 activation triggers nuclear accumulation of NF-B (25) .
PAK1, a member of the PAK family of serine/threonine kinases (26) , is activated by the Rho family GTP-binding proteins Rac1 and Cdc42 (27, 28) . Activation of these GTPases is induced by guanine nucleotide exchange factors, which catalyze the exchange of GDP for GTP (29) . In addition to activation, guanine nucleotide exchange factors may regulate downstream signaling events of Rac1 and Cdc42 (30) . These downstream signaling events include activation of many of the same pathways induced by LPS such as the JNK and p38 kinases (31) (32) (33) . Although Rac1 and Cdc42 have multiple effectors, the Rac1-and Cdc42-mediated increase in p38 activity is dependent on PAK1 (32) . Thus, there is accumulating evidence in the literature that the PAK1 pathway plays an important role in LPSmediated signal transduction.
Many studies have suggested a role for PAK1 in cytoskeletal reorganization and cell motility (34 -37) , and several physiologic signals such as thrombin, insulin, and epidermal growth factor have been reported to activate PAKs (28, 38, 39) . However, the role of PAK1 in transcriptional regulation is not well understood. In this work, we studied the role of the Cdc42/Rac/ PAK1 pathway in the LPS-induced regulation of the SR-BI promoter in macrophage RAW 264.7 cells.
MATERIALS AND METHODS
In Vivo Studies-Male C57BL/6 mice were injected intraperitoneally with 10 mg/kg LPS; and 48 h later, macrophages were harvested from the peritoneal cavity of vehicle-or LPS-treated animals. The cells were washed several times with cold RPMI 1640 medium (serum-free), and cell lysates were processed for Western blotting.
Cell Culture Studies-RAW 264.7 cells were grown to 80% confluency in 100-mm dishes in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Inc.) containing 10% fetal bovine serum. Growth medium was removed and replaced with DMEM containing 10% lipoproteindeficient serum, and the cells were incubated for an additional 24 h. LPS (1 g/ml) was added directly to fresh medium (DMEM containing 10% lipoprotein-deficient serum), and the cells were incubated for an additional 1, 3, 6, or 8 h and used for total RNA preparation or for an additional for 6, 12, 24, and 36 h and used for protein extract preparation.
mRNA Preparation and Quantification-Total RNA was prepared using the QIAGEN RNeasy mini kit, and DNase was treated according to the manufacturer's protocol (Ambion Inc.). mRNA expression was analyzed using real-time quantitative PCR on an Applied Biosystems Prism 7700 sequence detection system. Primer/probe sequences used for mouse SR-BI were as follows: SR-BI forward primer, 5Ј-AATGAC-AACGACACCGTGTCC-3Ј; reverse primer, 5Ј-TGCGACTTGTCAGG-CTGG-3Ј; and probe, 5Ј-FAM-CGTGGAGAACCGCAGCCTCCATT-TAMRA-3Ј, where FAM (6-carboxyfluorescein) and TAMRA (6-carboxytetramethylrhodamine) are fluorescent labels as described by the vendor. Final quantification was done using the comparative C T method according to the manufacturer's protocol (catalog no. 4304671, PE Biosystems), and data are reported as mRNA expression relative to glyceraldehyde-3-phosphate dehydrogenase internal control transcription.
Western Blotting-Cell protein extracts were prepared by removing the growth medium from cell cultures, washing the cells with cold phosphate-buffered saline, and immediately lysing them with radioimmune precipitation assay lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate, and protease inhibitors (Complete protease inhibitor mixture, Roche Molecular Biochemicals)). Whole cell lysates were centrifuged at 10,000 ϫ g for 10 min to remove cell debris. Protein concentration was determined in the supernatants using the Bradford assay (49) . Lysates were solubilized in Laemmli sample buffer, and 40 g of protein was loaded onto each lane of an 8 -18% Tris/glycine gel (Novex) and subjected to electrophoresis. After electrophoresis, separated proteins were transferred to nitrocellulose membranes and immunoblotted with a 1:1500 dilution of a rabbit anti-SR-BI polyclonal antibody (catalog number 400-104, Novus Biologicals) or a 1:1000 dilution of a mouse anti-glyceraldehyde-3-phosphate dehydrogenase monoclonal antibody (clone 6C6, Advanced Immunochemical) to verify equal amounts of protein loaded. After extensive washing with phosphate-buffered saline and 0.2% Tween 20, the blots were incubated with horseradish peroxidase-conjugated secondary antibodies (1:2000 dilution), and detection of immune complexes was carried out with the ECL Western blot detection system (Amersham Pharmacia Biotech).
Plasmid Constructs-A 739-base pair fragment (Ϫ896 to Ϫ157) and a 407-base pair fragment (Ϫ564 to Ϫ157) of the human SR-BI promoter were generated as outlined in the Advantage-GC genomic polymerase chain reaction kit (CLONTECH) using human genomic DNA as the template with the following primers: forward primers with NheI linkers (underlined), 5Ј-CCGGGCTAGCCAGTTGGAGCACATGGTCAGAATG-CAAG (primer 739) and 5Ј-CGCGGCTAGCAGAGGAGGAGAGGGAG-GAGGAGGGAAAAG (primer 407); and the reverse primer containing an XhoI linker (underlined), 5Ј-GGCGCTCGAGGGTGGCCAGTGGTT-TTATGCCCCATCG. The polymerase chain reaction products were gelpurified and directionally cloned into the pGL3-Basic vector (Promega) with NheI and XhoI digestion. 5Ј-Deletion constructs were generated from the 739-base promoter by linearization with NheI, followed by Bpu1102 (Ϫ413 to Ϫ157), ApaI (Ϫ255 to Ϫ157), or CspI (Ϫ199 to Ϫ157) digestion. The 5Ј-flanking sequence was numbered according to the start codon (ϩ1) as demonstrated by Cao et al. (6) . The shortened constructs were then gel-purified and religated. All SR-BI construct sequences were verified. The constitutively active Cdc42 Q61L and dominant-negative Cdc42 T17N expression constructs were a gift from Dr. Ian Macera (University of Virginia). The constitutively active Rac-V12 and dominant-negative RacN17 expression constructs were a gift from Onyx Pharmaceuticals, Inc. (Richmond, CA). All PAK1 expression constructs have been previously described (35, 36) and were provided by Dr. Jonathan Chernoff (Fox Chase Cancer Center, Philadelphia, PA). The pFB-Neo-NIK construct (provided by Jeffrey Marine, Pfizer) was generated by inserting 3 kilobase pairs of NIK coding sequence between the BamHI and NotI sites of the pFB-Neo retroviral vector. The p65, pRSV-␤gal, and NF-B response element constructs were kindly provided by Dr. Joseph Menetski (Pfizer).
Cell Transfections-The murine macrophage RAW 264.7 cell line was obtained from American Type Culture Collection (Manassas, VA) and maintained in DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 300 g/ml L-glutamine. Cells were seeded overnight at 200,000 cells/well in 24-well tissue culture plates (Costar Corp.). The medium was then replaced with 0.5 ml/well phenol red-free DMEM supplemented with 5% charcoal/dextran-treated bovine serum (Hyclone Laboratories). Cells were transfected in triplicate for 6 h with 100 l of Opti-MEM mixtures (Life Technologies, Inc.) containing a total of 0.5 g of experimental plasmid, 0.05 g of pRSV-␤gal normalization plasmid, and 1 l of LipofectAMINE 2000 (Life Technologies, Inc.). One ml of phenol red-free DMEM supplemented with 5% charcoal/dextran-treated bovine serum was added to each well after 6 h of transfection, and the cells were then treated with LPS (1 g/ml; Escherichia coli serotype 0111:B4, Sigma) or saline as indicated for 16 h. In cotransfection experiments, controls were cotransfected with empty pGL3-Basic vector to keep total DNA concentrations constant (empty pGL3-Basic vector luciferase values were confirmed to read at background levels). Luciferase and ␤-galactosidase samples were prepared with the luciferase assay system (Promega) and the Galacto-Star kit (Tropix Inc.), respectively. Luciferase and ␤-galactosidase activities were then measured in a microplate luminometer (EG&G Berthold).
Nuclear Extracts-RAW 264.7 cells were treated with 1 g/ml LPS or saline vehicle for 16 h. Cells were then rinsed with cold phosphatebuffered saline and lysed for 5 min in hypotonic buffer containing 0.2% Nonidet P-40, 20 mM HEPES, 20 mM NaF, 1 M Na 3 VO 4 , 1 M phosphate buffer, 1 M EGTA, 1 M dithiothreitol, 0.5 M phenylmethylsulfonyl fluoride, 0.125 M okadaic acid, and Complete protease inhibitor mixture (one tablet/50 ml). Cells were then scraped and centrifuged at 16,000 ϫ g for 20 s. Nuclear proteins were extracted from the pellet in hypotonic buffer containing 0.5 M NaCl and 25% glycerol with gentle rocking for 30 min, followed by centrifugation at 16,000 ϫ g for 20 min. Nuclear proteins contained in the supernatant were quantitated with the BCA protein assay kit (Pierce) and frozen at Ϫ80°C.
Electrophoretic Mobility Shift Assays-Four double-stranded oligonucleotide probes spanning the SR-BI promoter from Ϫ564 to Ϫ413 were synthesized and labeled with T4 polynucleotide kinase using [␥-32 P]ATP (3000 Ci/mmol) as the donor. Labeled probes were incubated with 10 g of nuclear extract protein for 30 min at room temperature. Samples were then separated on a 0.5ϫ Tris borate/EDTA and 5% acrylamide gel for 1 h at 300V. Gels were dried and developed with Hyperfilm MP (Amersham Pharmacia Biotech). Further analysis of the LPS-responsive region was conducted as described above with three shorter overlapping double-stranded oligonucleotide probes (A (Ϫ497 to Ϫ477), C (Ϫ487 to Ϫ466) and B (Ϫ476 to Ϫ456)) of the SR-BI promoter. Competition assays were conducted with a 10 -100-fold molar excess of unlabeled probes A, B, and C. Sp1 and AP-1 consensus sequence probes were obtained from Promega. Double-stranded MZF-1 consensus sequence probes were synthesized (Life Technologies, Inc.) as follows (sense strands shown): MZF-1A, 5Ј-GATCTAAAAGTGGGGAGAAAA; and MZF-1B, 5Ј-GATCCGGCTGGTGAGGGGGAATCG. Competition assays with transcription factor-binding site probes were conducted with a 100-fold molar excess of unlabeled probe.
Statistical Analysis-The unpaired t test (two-tailed) was used to compare mean experimental values with the corresponding control values as described in the figure legends. (16) . These data were confirmed using the macrophage-like RAW 264.7 cells. LPS (1 g/ml) treatment of these cells resulted in a time-dependent decrease in SR-BI mRNA levels, with peak reductions at 6 h post-treatment (Fig.  1A) . Western blot analysis of RAW 264.7 cells treated with LPS also indicated a dramatic reduction in SR-BI protein levels (Fig. 1B) . In vivo confirmation of these results was obtained using peritoneal macrophages from LPS-treated C57BL/6 mice. Intraperitoneal injection of these animals with LPS (10 mg/kg) resulted in nearly complete elimination of SR-BI protein in peritoneal macrophages as determined by Western blot analysis, whereas it had very minimal effects on the levels of the ␤-actin control (Fig. 1C) . Based on these findings, we conclude that LPS has a powerful negative effect on SR-BI expression in macrophage cells both in vitro and in vivo.
RESULTS

LPS Inhibits SR-BI Expression in Vitro and in Vivo-LPS down-regulates SR-BI expression in human monocytes and macrophages in vitro
LPS Inhibits SR-BI Promoter Activity-LPS has been demonstrated to down-regulate SR-BI mRNA levels in human monocytes and macrophages (16) ; however, the effects of LPS on the transcriptional activity of the SR-BI promoter have not been studied. To evaluate the effect of LPS on SR-BI promoter activity, RAW 264.7 cells were transfected with the SR-BI Ϫ896/Ϫ157 promoter construct and treated for 16 h with LPS (1 g/ml) or saline as a control. As shown in Fig. 2 , the combined results from six independent experiments each performed in triplicate demonstrate that LPS treatment resulted in a significant (p Ͻ 0.001) reduction in SR-BI Ϫ896/Ϫ157 promoter activity. To delineate the LPS-responsive region, shortened promoter constructs were generated and transfected into RAW 264.7 cells. As shown in Fig. 3 , LPS treatment resulted in a significant decrease in the activity of the Ϫ896/ Ϫ157 and Ϫ564/Ϫ157 promoter constructs; however, LPS did not alter the activity of the shorter promoter constructs. These results indicate that the LPS-responsive region lies between Ϫ564 and Ϫ413 of the promoter.
The Serine/Threonine Kinase PAK1 Inhibits SR-BI Promoter Activity-Given that LPS has been demonstrated to activate PAK1 in RAW 264.7 cells (25) and that PAKs can activate important transcriptional regulatory cascades such as NF-B, p38 MAPK, and JNK (25, 32, 33) , the ability of PAK1 to down-regulate the SR-BI promoter was tested. As shown in Figs. 4 and 6 , cotransfection of RAW 264.7 cells with the constitutively active PAK1 construct (T423E) and the SR-BI Ϫ896/ Ϫ157 promoter construct resulted in a significant reduction in 
promoter activity. Cotransfection of the kinase-deficient PAK1 construct (K299R) also significantly decreased the activity of the promoter (Figs. 4 and 6 ). These results demonstrate that PAK1-mediated down-regulation of the SR-BI promoter is independent of PAK1 kinase activity. No additional decrease in promoter activity was observed in PAK-transfected cells when treated with LPS (data not shown), suggesting that PAK1 mediates the LPS-induced decrease in promoter activity.
Rac and Cdc42 Inhibit the SR-BI Promoter-To provide further evidence that the Cdc42/Rac/PAK1 pathway is involved in regulation of the SR-BI promoter, we tested the ability of known upstream activators of PAK1 to mimic the PAK1 response. It is well established that the small Gproteins Rac and Cdc42 activate PAK1 (27) . To evaluate the role of these G-proteins in the regulation of the SR-BI promoter, RAW 264.7 cells were cotransfected with constitutively active or dominant-negative G-protein expression constructs and the SR-BI Ϫ896/Ϫ157 promoter construct. As demonstrated in Fig. 5 , expression of the constitutively active forms of Cdc42 (Q61L) and Rac (RacV12) significantly inhibited promoter activity. As in the PAK1 transfectants, no additional decrease in promoter activity was observed when constitutively active Cdc42-or Rac-transfected cells were treated with LPS or when cells were transfected with both active G-protein and PAK1 constructs (data not shown). These findings suggest that Cdc42 and Rac mediate the LPSinduced down-regulation of the SR-BI promoter. Furthermore, as shown in Fig. 5 , expression of the dominant-negative Cdc42 T17N mutant resulted in a 2-fold increase (p Ͻ 0.005) in the activity of the promoter, whereas cotransfection of the dominant-negative RacN17 mutant resulted in a smaller yet significant increase (p Ͻ 0.05) in the activity of the promoter. These dominant-negative G-protein constructs exert their negative effect by trapping the guanine nucleotide exchange factors, which are necessary for the disassociation of GDP and subsequent GTP binding that activate these G-proteins (29) . These results suggest that endogenous active Cdc42 and Rac inhibit the SR-BI promoter under basal conditions. In addition, when cells that were cotransfected with the dominant-negative Cdc42 or Rac constructs were treated with LPS, the response to LPS was blunted. Although LPS treatment resulted in a reduction in promoter activity compared with the dominant-negative constructs alone, this decrease was not significantly different from that in the control cells transfected with the SR-BI promoter alone (Fig. 5) .
Rac and Cdc42 Are Required for PAK1-mediated Down-regulation of SR-BI Promoter Activity-To evaluate the role of these G-proteins in PAK1-mediated down-regulation of the promoter, double mutant PAK1 constructs containing mutations in both the kinase domain (K299R) and the G-proteinbinding domain (H83L and H86L) were cotransfected with the promoter construct. As shown in Fig. 6 , PAK1-mediated decreases in SR-BI promoter activity were attenuated under both the kinase-deficient and constitutively active PAK1 conditions when the G-protein-binding domain was also mutated. These results demonstrate that PAK1-mediated decreases in SR-BI promoter activity are dependent on a functional G-proteinbinding domain and suggest that the Cdc42-and Rac-induced decreases in promoter activity are due at least in part to interactions with PAK1.
NF-B Is Not Involved in the LPS-mediated Down-regulation
FIG. 3. The LPS-responsive region lies between ؊564
and ؊413 of the SR-BI promoter. The 5Ј-deletion SR-BI Ϫ413/Ϫ157, Ϫ255/Ϫ157, and Ϫ199/Ϫ157 promoter constructs were generated from the Ϫ896/Ϫ157 promoter construct with restriction enzymes as described under "Materials and Methods." Constructs were transiently transfected into RAW 264.7 cells and treated for 16 h with LPS (1 g/ml) or saline as a control. Transfection efficiency was normalized with a pRSV-␤gal plasmid. Means Ϯ S.E. are shown from a representative of three independent experiments, each performed in triplicate. LPS treatment significantly decreased the activity of the Ϫ896/Ϫ157 and Ϫ564/Ϫ157 promoters (p Ͻ 0.05). Lucif/BGal, luciferase/␤-galactosidase. (40, 41) . More recently, PAK1 activity has been demonstrated to be required for activation of NF-B in RAW 264.7 cells (25) . To evaluate the role of NF-B in the LPS-induced down-regulation of the SR-BI promoter, RAW 264.7 cells were cotransfected with a p65 expression construct. As shown in Fig. 7B , expression of p65 resulted in an 18-fold increase in an NF-B response elementluciferase construct. However, cotransfection of the p65 expression construct had minimal effects on the activity of SR-BI promoter constructs (Fig. 7A) . To further confirm that activation of the NF-B pathway did not alter SR-BI promoter activity, an upstream activator of NF-B, NIK, was coexpressed with the SR-BI promoter. As shown in Fig. 7D , overexpression of NIK resulted in a 5-fold increase in the activity of the NF-B response element-luciferase construct. However, as in the p65 experiments, NIK had no effect on SR-BI promoter activity (Fig. 7C) . These results suggest that activation of the NF-B pathway does not alter SR-BI transcriptional activity. (Fig.  2) , four double-stranded oligonucleotide probes spanning the LPS-responsive region were synthesized and labeled for gel shift analysis. As shown in Fig. 8A , DNA-protein complexes were observed with each of the four probes (GS1-4). However, GS-3 (Ϫ497 to Ϫ456) revealed a prominent DNA-protein complex under control conditions, which was inhibited in the LPStreated cells. GS-3 was then further divided into three probes (A, B, and C) and evaluated by gel shift analysis. As shown in Fig. 8B , the protein-binding region was confined to probe B, spanning Ϫ476 to Ϫ456. As observed in GS-3 binding, treatment of cells with LPS inhibited protein binding to probe B. This binding was shown to be specific, as competition experiments with increasing concentrations of unlabeled probe B blocked formation of the complex, whereas increasing concentrations of unlabeled probes A and C had no effect on the DNA-protein complex (Fig. 8C) . Transcription factor data base analysis of probe B revealed two putative cis-elements: a heat shock factor (HSF) element and an MZF-1 element (Fig. 9A) . To determine whether these putative sites were mediating protein binding to probe B, point mutations at consensus sites were made and evaluated by gel shift analysis. As depicted in Fig.  9A , a point mutation of the HSF element (M1) did not alter protein binding, whereas a point mutation of the MZF-1 element (M2) blocked protein binding. These results are supported by analysis of probe C, which contained the HSF element, but not the MZF-1 element, and did not demonstrate DNA-protein interaction. However, two different consensus sequences for MZF-1 as identified by Morris et al. (42) failed to compete for binding with probe B (Fig. 9B) , suggesting that MZF-1 is not a component of the DNA-protein complex. In addition, AP-1 and Sp1 consensus probes also failed to block DNA-protein interaction with probe B (Fig. 9C) . To confirm that the MZF-1-like element was involved in the LPS response, the M2 point mutation was introduced in the SR-BI Ϫ896/Ϫ157 promoter construct. Transient transfection experiments with the M2 construct demonstrated a 30% decrease in the LPSmediated repression of the promoter. Together, these results suggest that LPS inhibits the binding of a novel transcription factor that binds to an MZF-1-like element and activates transcription of the human SR-BI promoter.
of the SR-BI Promoter-It is well established that LPS activates NF-B in the monocyte/macrophage
LPS Inhibits Transcription Factor Binding to an MZF-1-like Element in the SR-BI Promoter-To further delineate the LPSresponsive region of the SR-BI promoter (Ϫ564 to Ϫ413)
DISCUSSION
Previous studies have documented SR-BI expression in human monocytes and macrophages (2, 8, 9) and in the murine macrophage cell line RAW 264.7 (4). It has also been shown that LPS down-regulates SR-BI mRNA and protein levels in monocytes and macrophages (16) . The results in this study confirm these in vitro findings and demonstrate for the first time that LPS down-regulates SR-BI protein levels in macrophages in vivo. The finding in this study that LPS decreases SR-BI promoter activity in RAW 264.7 cells provided a system to begin elucidating the signaling pathways involved in LPS regulation of the SR-BI promoter in macrophage cells.
Although LPS signaling is complex and not completely un- derstood, it has been shown to involve activation of PAK1 and to lead to nuclear accumulation of NF-B in RAW 264.7 cells (25) . The results presented in this study show that PAK1 inhibits SR-BI promoter activity and suggest that LPS-mediated reduction in SR-BI promoter activity is mediated by the PAK1 pathway. Importantly, PAK1 inhibition of the SR-BI promoter was shown to be independent of PAK1 kinase activity since expression of either constitutively active or kinase-deficient PAK1 resulted in a similar decrease in promoter activity. Several studies have demonstrated kinase-independent effects of PAK1 on cytoskeletal regulation (36, 37, 43) ; however, the kinase-independent effect of PAK1 on transcriptional regulation observed in this study is novel. Recent studies showed that PAK1 up-regulates the vascular endothelial growth factor promoter in MCF-7 cells. The vascular endothelial growth factor promoter results provide additional evidence that PAK1 can alter transcriptional regulation; however, this regulation was shown to be dependent on the kinase activity of PAK1 (44) . Recent studies provide evidence that the kinase-independent effects of PAK1 are due to protein-protein interactions that occur upon recruitment of PAK1 to the plasma membrane. The kinase-independent effect of PAK1 on neurite outgrowth in PC-12 cells requires targeting of PAK1 to the plasma membrane and is dependent on structural features in both the Nand C-terminal domains of the molecule (43) . In addition, PAKs have been demonstrated to interact with a variety of proteins at the plasma membrane such as the Cool/Pix proteins (45, 46) . Our results support the previous findings of kinase-independent effects of PAK1 and furthermore demonstrate that these effects can alter transcriptional regulatory mechanisms.
The importance of protein-protein interactions for PAK1 activity was also documented in this study. The results show that the PAK1-mediated reduction in SR-BI promoter activity was dependent on Rac and Cdc42 since PAK1 mutants unable to bind these GTPases had significantly less activity than the PAK1 mutants with intact GTPase-binding domains. Although Cdc42 and Rac are known to trigger the kinase activity of PAK1 (27) , our results indicate that these GTPases have an additional role in mediating the effects of PAK1 on SR-BI transcriptional regulation perhaps through recruitment of PAK1 to the plasma membrane. Additional evidence that Rac and Cdc42 were intimately involved in the down-regulation of SR-BI promoter activity was shown by the significant decreases in promoter activity in cells transfected with the constitutively active GTPases. Furthermore, the dominant-negative Rac and Cdc42 proteins blocked the LPS-mediated reduction in SR-BI promoter activity and elevated the basal activity of the promoter. Taken together, these results strongly suggest a role for Cdc42, Rac, and PAK1 in the LPS-mediated decrease in SR-BI promoter activity. The kinase-independent effects shown in this study in conjunction with the observations noted by others suggest a model for PAK1 "activation" in which the function of PAK1 is determined by both the kinase activity of the enzyme and, perhaps more importantly, the assembly of signaling complexes.
The observation that LPS inhibits SR-BI promoter activity suggests that two basic mechanisms may be involved. LPS either results in a loss of transcriptionally active DNA-protein interactions or leads to formation of repressive DNA-protein complexes. Gel shift analyses of the LPS-responsive region as defined by 5Ј-deletion constructs suggested that LPS inhibited binding of transcriptional activators to the SR-BI promoter rather than leading to formation of repressive DNA-protein interactions. Gel shift experiments narrowed the putative LPS- FIG. 8 . Gel shift analysis of the LPSresponsive region. A, nuclear extracts from RAW 264.7 cells treated for 16 h with LPS or saline as a control (C) were incubated with four double-stranded oligonucleotide probes spanning the LPS-responsive region (GS1-4) as described under "Materials and Methods." GS-3 (Ϫ497 to Ϫ456) demonstrated a strong difference in DNA-protein complex formation, with decreased complex observed in the LPS-treated cells (arrow). B, GS-3 was further divided into three probes (A, B, and C) and evaluated by gel shift analysis. The protein-binding region was confined to probe B, spanning Ϫ476 to Ϫ456; and LPS inhibited protein binding to probe B. C, competition experiments with increasing concentrations of unlabeled probe B blocked formation of the complex, whereas increasing concentrations of unlabeled probes A and C had no effect on the DNA-protein complex. *B, labeled probe alone.
responsive region of the human SR-BI promoter to Ϫ476 to Ϫ456. Importantly, the steroidogenic factor-1 site previously demonstrated to regulate human SR-BI promoter activity in adrenocortical cells (6) is located at positions Ϫ218 to Ϫ212 and does not appear to be a major mediator of basal transcriptional activity in RAW 264.7 cells, as significant decreases in basal activity were observed in the construct containing the steroidogenic factor-1 site (Ϫ255 to Ϫ157). Together, these observations indicate that transcriptional regulation of SR-BI is cell type-dependent.
Transcription factor data base analysis of the putative LPSresponsive region indicated that an MZF-1-like element was involved; and indeed, a point mutation in this element at position Ϫ464 mimicked the LPS-induced decrease in protein binding to the region. However, MZF-1 consensus probes were unable to compete for binding, suggesting that the MZF-1 protein was not a component of the DNA-protein complex inhibited by LPS. Given that this LPS-responsive region is Grich, characteristic of Sp1-binding sites, and that Sp1 has been implicated in transcription of the rat SR-BI promoter (17), we tested the possibility that the LPS-responsive region was binding the Sp1 protein. However, gel shift competition assays with an Sp1 consensus probe indicated that Sp1 was not a member of the protein complex disrupted by LPS. In addition, experiments ruled out roles for AP-1 and NF-B in the LPS-mediated reduction in promoter activity. Together, these results suggest that a novel transcription factor binds to Ϫ476 to Ϫ456 of the human SR-BI promoter and drives basal transcription in the macrophage. In addition, these results suggest that LPS disrupts binding of this factor, thereby inhibiting SR-BI transcription. Indeed, a point mutation in the MZF-1-like element, although not abolishing the LPS response, did reduce the LPS response, suggesting that the LPS effect is due in part to the MZF-1-like element. Further experiments are needed to determine the nature of the factor binding to the MZF-1-like element and to decipher additional LPS-responsive regions in the SR-BI promoter.
Although the extracellular milieu in an atherosclerotic plaque is complex, thus exposing foam cells to a multitude of stimuli, recent studies in platelets provide further evidence that PAK1 may be an important physiologic regulator of SR-BI in the atherosclerotic vessel. The coagulation protease, thrombin, has been shown to activate PAK1 in platelets (38) . In addition, ligation of the thrombin protease-activated receptor (PAR-1) is known to activate Cdc42 and Rac in platelets (47) . Importantly, the thrombin receptor has been detected in macrophages (48) , and thrombin is likely present in the atherosclerotic vessel wall. These observations raise the possibility that thrombin-induced activation of PAK1 may be an important physiologic mechanism of SR-BI regulation in the foam cell and warrant further exploration into the role of PAK1 activity in cholesterol homeostasis in the atherosclerotic vessel wall.
In summary, we have documented that LPS and the PAK1 pathway down-regulate human SR-BI promoter activity in the macrophage. These results support the hypothesis that inflammatory mediators exacerbate foam cell formation via downregulation of the SR-BI receptor in the macrophage.
